Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	129.87	24.02	0.88	-1,002	175.07	528.45
Depreciation & Amortization	1.84	1.88	2.01	1.58	1.42	1.52
Loss (Gain) From Sale of Assets	0	0.09	0.08	-	0	0.09
Asset Writedown & Restructuring Costs	-	-	-	1,095	-	-
Stock-Based Compensation	14.32	17.25	29.85	32.01	27.05	22.28
Other Operating Activities	63.8	44.16	71.55	45.36	67.41	-308.18
Change in Accounts Receivable	-26.56	35.15	47.24	0.92	7.99	7.71
Change in Accounts Payable	0.88	6.2	-20.21	12.38	-8.12	-2.64
Change in Other Net Operating Assets	1.41	-1.7	-27.85	-2.03	2.94	12.66
Operating Cash Flow	185.56	127.04	103.55	183.43	273.76	261.9
Operating Cash Flow Growth	518.83%	22.69%	-43.55%	-33.00%	4.53%	55.12%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-0	-0.03	-0.14	-0.27	-0.14	-0.27
Cash Acquisitions	-	-	-	-1,026	-	-
Investing Cash Flow	-0	-0.03	-0.14	-1,026	-0.14	-0.27

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	-	-	150	400	-	-
Long-Term Debt Repaid	-	-	-265	-100	-120.7	-
Net Debt Issued (Repaid)	-200	-	-115	300	-120.7	-
Issuance of Common Stock	0.43	0.22	11.01	6.36	9.54	19.58
Repurchase of Common Stock	-	-	-0.74	-	-126.39	-24.13
Other Financing Activities	-	-	-2.25	-29.2	-	-
Financing Cash Flow	-199.58	0.22	-106.97	277.16	-237.55	-4.55

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	0.3	-0.33	-0.03	-0.05	-	-
Net Cash Flow	-13.73	126.9	-3.6	-565.78	36.07	257.08

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	185.55	127.01	103.41	183.15	273.63	261.63
Free Cash Flow Growth	519.84%	22.82%	-43.54%	-33.06%	4.58%	56.67%
Free Cash Flow Margin	47.66%	42.89%	29.43%	41.37%	66.64%	63.23%
Free Cash Flow Per Share	1.12	0.78	0.65	1.18	1.47	1.59
Levered Free Cash Flow	121.83	111.69	80.71	204.13	161.46	170.05
Unlevered Free Cash Flow	142.25	132.16	101.51	217.5	166.21	189.52

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	30.33	30.33	32.56	13.55	5.75	7.22
Cash Income Tax Paid	3.54	3.54	8.41	9.95	4.62	3.45
Change in Working Capital	-24.27	39.65	-0.82	11.28	2.82	17.73

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 12, 2026

Data Sources Report a data error